Eventide Asset Management’s United Therapeutics UTHR Stock Holding History

Eventide Asset Management’s Portfolio UTHR Stock Details UTHR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$14.7M	Sell	27,101 -1,451	-5%	-$817K	0.2%	131
2026 Q1	$16.9M	Sell	28,552 -18,452	-39%	-$9.19M	0.28%	113
2025 Q4	$22.9M	Sell	47,004 -15,237	-24%	-$7.1M	0.36%	96
2025 Q3	$26.1M	Buy	62,241 +15,000	+32%	+$5.04M	0.43%	85
2025 Q2	$13.6M	Hold	47,241	–	–	0.24%	114
2025 Q1	$14.6M	Sell	47,241 -20,584	-30%	-$7.05M	0.29%	101
2024 Q4	$23.9M	Hold	67,825	–	–	0.44%	80
2024 Q3	$24.3M	Hold	67,825	–	–	0.42%	74
2024 Q2	$21.6M	Buy	+67,825	New	+$18M	0.37%	87

Other funds holding UTHR

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Norges Bank Oslo, Norway $1T AUM

Eventide Asset Management's UTHR Position: Q2 2026 in Review

Eventide Asset Management reduced its United Therapeutics (UTHR) stake by 5.1% in Q2 2026, selling an estimated $817K and leaving 27,101 shares worth $14.7M. The position accounts for 0.2% of the portfolio, ranked #131.

Eventide Asset Management first reported a position in UTHR in Q2 2024 and has held it in 9 quarters since. The position peaked at $26.1M in Q3 2025. 878 funds tracked by Wall St. Rank hold UTHR as of Q2 2026.

Eventide Asset Management held 27,101 shares of United Therapeutics worth $14.7M as of Q2 2026.
Eventide Asset Management sold 1,451 United Therapeutics shares in Q2 2026, an estimated $817K.
United Therapeutics made up 0.2% of Eventide Asset Management's portfolio in Q2 2026, its #131 holding.
Eventide Asset Management first reported a position in United Therapeutics in Q2 2024 and has held it in 9 quarters since.
Eventide Asset Management's United Therapeutics position peaked at $26.1M in Q3 2025.
878 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2026.

Based on Eventide Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.